Microbial gamma-aminobutyric acid synthesis: a promising approach for functional food and pharmaceutical applications.
Level 5 - mechanism / opinion, no new human data
Narrative mini-review without systematic search methodology or primary human trial data.
PubMed 39673306 · doi:10.1093/lambio/ovae122
What was done
The authors conducted a narrative mini-review summarizing microbial synthesis of gamma-aminobutyric acid (GABA), focusing on producing microorganisms (such as lactic acid bacteria and Bifidobacterium), the glutamate decarboxylase enzymatic pathway, yield optimization techniques, and proposed health applications.
What was found
The abstract reports that strains including Lactobacillus brevis, Lactobacillus plantarum, and Bifidobacterium species convert L-glutamate to GABA via glutamate decarboxylase. It notes potential applications based on reported benefits of GABA, including blood pressure reduction, anxiety reduction, and sleep and cognitive improvements. No quantitative yields, optimization metrics, or clinical effect sizes are reported in the abstract.
Why it matters
Microbial biosynthesis offers a sustainable, cost-effective alternative to chemical synthesis, enabling in situ GABA enrichment in fermented foods and nutraceuticals.
Limits
The review is narrative rather than systematic, presenting no primary experimental data, quantitative yield comparisons, or evaluation of human clinical trial evidence.
Cited by
- supports GABA is synthesized from glutamate via glutamic acid decarboxylase, while glutamate is an excitatory neurotransmitter that activates AMPA and NMDA receptors.